The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

Tom Williams is using his experience to encourage others to register as organ donors, calling 2025 his best year since a life ...

The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

Cystic fibrosis (CF) and pulmonary fibrosis (PF) are two chronic conditions that damage the lungs. Treatment for both aims to improve breathing, manage symptoms, and prevent further lung damage. Your ...

Discover how weather conditions affect idiopathic pulmonary fibrosis (IPF) symptoms and learn practical tips to manage your ...

"We are reaching the point where a lung transplant will be necessary," Dr. Are Martin Holm said The Royal House of Norway ...

Marit, wife of future king, Crown Prince Haakon of Norway is to go under the knife for a rare pulmonary fibrosis issue and ...

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...